ArticleFrontiers in public health2026
Pharmacoeconomic evaluation of first-line tislelizumab for extensive-stage small cell lung cancer using a comparative validation of traditional survival and machine learning models.
Yang Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.